METHOD OF INHIBITING DOPAMINERGIC CELL DEATH
Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications for reducing dopaminergic cell death.
1 . A method of reducing dopaminergic cell death in a subject in need thereof, comprising administering to said subject an effective amount of recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β.
2 . The method of claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β.
3 . The method of claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β.
4 . The method of claim 1 , wherein the Type I Neuregulin-1 β isoform has an isoelectric point (pI) of about 4 to about 10.
5 . The method of claim 1 , wherein the Type 1 Neuregulin-1 β isoform is a modified polypeptide, wherein the modifications are selected from phosphorylation, glycosylation, methylation, myristoylation, oxidation and any combination thereof.
6 . A method of promoting neuroprotection comprising administering a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β to a subject in need thereof.
7 . The method of claim 6 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β.
8 . The method of claim 6 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β.
9 . The method of claim 6 , wherein the Type I Neuregulin-1 β isoform has an isoelectric point (pI) of about 4 to about 10.
10 . The method of claim 6 , wherein the Type I Neuregulin-1 β isoform is a modified polypeptide, wherein the modifications are selected from phosphorylation, glycosylation, methylation, myristoylation, oxidation and any combination thereof.
11 . A method of enhancing memory in a subject in need thereof comprising administering to said subject a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β.
12 . The method of claim 11 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β.
13 . The method of claim 11 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β.
14 . The method of claim 11 , wherein the Type I Neuregulin-1 β isoform has an isoelectric point (pI) of about 4 to about 10.
15 . The method of claim 11 , wherein the Type I Neuregulin-1 β isoform is a modified polypeptide, wherein the modifications are selected from phosphorylation, glycosylation, methylation, myristoylation, oxidation and any combination thereof.
16 . A method of effecting antipsychotic activity in a subject in need thereof comprising administering to said subject a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β.
17 . The method of claim 16 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β.
18 . The method of claim 16 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β.
19 . The method of claim 16 , wherein the Type I Neuregulin-1 β isoform has an isoelectric point (pI) of about 4 to about 10.
20 . The method of claim 16 , wherein the Type I Neuregulin-1 β isoform is a modified polypeptide, wherein the modifications are selected from phosphorylation, glycosylation, methylation, myristoylation, oxidation and any combination thereof.